Delay Resistance to Avastin in Recurrent Glioblastoma

A Randomized Phase II Trial of Standard Dose Bevacizumab versus Low Dose Bevacizumab plus Lomustine (CCNU) In Adults with Recurrent Glioblastoma

Objective:

- To test the hypothesis that lower doses of bevacizumab in combination with cytotoxic chemotherapy will improve outcomes compared to standard dose bevacizumab

Eligibility Criteria:

- Recurrent glioblastoma/gliosarcoma
- Up to two prior relapses
- Karnofsky performance status > 60
- No prior gliadel
- No prior antiangiogenic agent exposure
- No history of intracranial bleeding

Procedures:

- Visit to MD Anderson every 6 weeks
- Can receive bevacizumab through referring physician
- Do blood samples every 6 weeks at MD Anderson
- Have MRI every 6 weeks

Benefits for Patients:

- Participate on a novel clinical trial
- Potential to delay or prevent resistance to antiangiogenic therapy
- Assist with the discovery and validation of biomarkers of response and resistance to bevacizumab

Protocol # 2009-0597 (NCT01067469)

Principal Investigator:
John de Groot , MD

Schedule an appointment or make referral online at https://my.mdanderson.org or call (713) 792-7728. For more information about the study, contact John de Groot, MD, Neuro-Oncology, at (713)792-7255 or jdegroot@mdanderson.org; Teresa Hanna, RN, at (713) 563-1603, or thanna@mdanderson.org

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

For information on related articles or references for this study, visit http://physicianrelations.org or http://clinicaltrials.gov/ct2/show/NCT01067469